New York State Common Retirement Fund Acquires 2,301 Shares of West Pharmaceutical Services, Inc. $WST

New York State Common Retirement Fund boosted its holdings in West Pharmaceutical Services, Inc. (NYSE:WST) by 3.1% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 77,506 shares of the medical instruments supplier’s stock after buying an additional 2,301 shares during the quarter. New York State Common Retirement Fund’s holdings in West Pharmaceutical Services were worth $16,958,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of WST. Zions Bancorporation National Association UT bought a new stake in shares of West Pharmaceutical Services in the first quarter worth approximately $25,000. Quarry LP purchased a new stake in West Pharmaceutical Services in the first quarter worth approximately $27,000. Vermillion & White Wealth Management Group LLC boosted its holdings in West Pharmaceutical Services by 193.9% in the second quarter. Vermillion & White Wealth Management Group LLC now owns 144 shares of the medical instruments supplier’s stock worth $32,000 after purchasing an additional 95 shares during the last quarter. CVA Family Office LLC grew its position in West Pharmaceutical Services by 573.3% in the 2nd quarter. CVA Family Office LLC now owns 202 shares of the medical instruments supplier’s stock worth $44,000 after purchasing an additional 172 shares during the period. Finally, Cromwell Holdings LLC raised its stake in West Pharmaceutical Services by 587.5% during the 2nd quarter. Cromwell Holdings LLC now owns 220 shares of the medical instruments supplier’s stock valued at $48,000 after buying an additional 188 shares during the last quarter. Institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Stock Performance

Shares of WST opened at $273.32 on Wednesday. The business has a 50-day simple moving average of $272.31 and a two-hundred day simple moving average of $246.87. The company has a quick ratio of 2.18, a current ratio of 2.87 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services, Inc. has a 52 week low of $187.43 and a 52 week high of $348.90. The stock has a market cap of $19.66 billion, a price-to-earnings ratio of 40.49, a PEG ratio of 4.09 and a beta of 1.08.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, October 23rd. The medical instruments supplier reported $1.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.67 by $0.29. The company had revenue of $804.60 million during the quarter, compared to the consensus estimate of $788.42 million. West Pharmaceutical Services had a return on equity of 18.16% and a net margin of 16.29%.The firm’s revenue was up 7.7% on a year-over-year basis. During the same period in the previous year, the company posted $1.85 EPS. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS. On average, analysts expect that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on WST shares. Cowen started coverage on West Pharmaceutical Services in a research note on Wednesday, October 29th. They issued a “buy” rating on the stock. Redburn Partners set a $311.00 target price on West Pharmaceutical Services in a report on Monday, September 15th. Rothschild Redb raised West Pharmaceutical Services to a “strong-buy” rating in a research report on Monday, September 15th. TD Cowen initiated coverage on West Pharmaceutical Services in a research note on Wednesday, October 29th. They set a “buy” rating and a $350.00 price target for the company. Finally, Zacks Research cut shares of West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 23rd. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $343.36.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.